新股消息 | 大医集团递表港交所 核心产品CybeRay是全球首个实时影像引导伽玛放射外科系统

Core Viewpoint - Xi'an Dayi Group Co., Ltd. has submitted an application to the Hong Kong Stock Exchange, with CITIC Securities International, Pudong Development Bank International, and Minyin Capital as joint sponsors [1] Company Overview - Dayi Group is a global leader in innovative radiosurgery solutions, aiming to build a next-generation intelligent radiosurgery ecosystem since its establishment in 2011 [3] - The core product, CybeRay, is the world's first real-time image-guided gamma radiosurgery system, approved by the FDA in March 2021 and by the National Medical Products Administration of China in July 2022, currently in the research phase for expanding indications [3] - Another flagship product, TaiChiRT Pro, is the first integrated X/gamma-ray radiosurgery system to receive breakthrough medical device designation from the FDA [3] Market Potential - The current focus of radiosurgery is on tumor treatment, but potential applications are expanding into non-tumor indications [4] - The global market size for radiosurgery is projected to grow from $92.4 billion in 2024 to $138.9 billion by 2030, with a compound annual growth rate (CAGR) of 7.0% [4] - In China, the tumor radiotherapy market is expected to increase from RMB 59.4 billion to RMB 105.8 billion, with a CAGR of 10.1% [4] - The U.S. tumor radiotherapy market is estimated to grow from $50.3 billion to $68.0 billion, with a CAGR of 5.2% [4] Technological Advancements - Dayi Group is transitioning treatment modalities from traditional invasive and minimally invasive surgeries to non-invasive procedures, ensuring patient health while delivering breakthrough clinical outcomes [4] - The company integrates various radiation therapy technologies, multi-ray imaging techniques, intelligent software platforms, and smart algorithms to create a precise radiosurgery treatment system covering both tumor and non-tumor indications [4][6] Financial Performance - For the fiscal years 2023 and 2024, Dayi Group's revenue is projected to be approximately RMB 261 million and RMB 264 million, respectively [6] - The company anticipates losses of approximately RMB 69.78 million in 2023 and RMB 94.57 million in 2024 [6][7] - The financial data indicates a gross profit of RMB 128.17 million in 2023, increasing to RMB 138.82 million in 2024 [7]